Prelude Therapeutics Inc 8-K

What Happened
Prelude Therapeutics Incorporated (PRLD) filed a Current Report on Form 8-K on May 12, 2026 to announce its financial results for the three months ended March 31, 2026. The company furnished a press release reporting those results (Exhibit 99.1) and provided updated investor presentation materials for management use (Exhibit 99.2). The report was signed by Bryant Lim, Chief Financial Officer and Chief Legal Officer. The disclosures were furnished under Item 2.02 (results of operations) and Item 7.01 (Regulation FD disclosure).

Key Details

• Filing date: May 12, 2026; period covered: quarter ended March 31, 2026.
• Press release announcing quarterly results attached as Exhibit 99.1.
• Investor presentation materials attached as Exhibit 99.2 and to be used in management presentations.
• Information in the 8-K and exhibits is furnished (not “filed”) under the Exchange Act.

Why It Matters
This 8-K signals that Prelude has released its latest quarterly financial results and updated investor materials — both of which may include information on earnings, revenue, cash position, and program updates important to shareholders. Retail investors should review the attached press release and presentation for the specific financial figures and operational details, since the Form 8-K itself mainly notes the furnishing of those materials rather than including the detailed numbers.